
Researchers studied Liver X receptor (LXR) agonists alone and in combination with carboplatin in breast cancer models. In vitro experiments showed reduced tumor cell proliferation in estrogen receptor-positive cells, while in vivo activation of LXRs with carboplatin enhanced growth inhibition in basal-like breast cancer. Proteomic analysis revealed differences in protein expression related to Akt activity, cell-cycle progression, and DNA repair. The combination treatment inhibited E2F transcription factor targets and affected cholesterol homeostasis in basal-like breast cancer.
Like
Save
Share